Table IV. Time From Most Recent Increase in Dose of Step 1 (Blinded) Antihypertensive Medication Prior to Onset of Angioedema in ALLHAT Participants*.

	Number (%) of Participants With Angioedema
Time from Most Recent Step i Dose Increase to Onset of Angioedema	C	A	L	D	Total
No dose increase†	4 (50)	0	20 (54)	3 (60)	27 (51)
1–2 d	0	0	0	0	0
3–7 d	0	1	2	0	3
Total with dose increase within first week†	0	1 (33)	2 (5)	0	3 (6)
8–14 d	0	0	2	0	2
15–30 d	0	1	2	1	4
Total with dose increase within first month†	0	2 (66)	6 (16)	1 (20)	9 (17)
31–60 d	0	0	0	0	0
61–90 d	0	0	1	0	1
Total with dose increase within first 3 months†	0	2 (66)	7 (19)	1 (20)	10 (19)
91–182 d	1	1	1	0	3
6 mo–1 yr	1	0	4	1	6
ALLHAT indicates Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial; C, chlorthalidone; A, amlodipine; L, lisinopril; D, doxazosin. *For participants who experienced more than one episode of angioedema, only the first is considered. †Values are cumulative.